Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Anticancer Drugs

Retrieve available abstracts of 6 articles:
HTML format
Text format



Single Articles


    September 2018
  1. SONG MM, Makena MR, Hindle A, Koneru B, et al
    Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.
    Anticancer Drugs. 2018 Sep 27. doi: 10.1097/CAD.0000000000000696.
    PubMed     Text format     Abstract available


    November 2017
  2. LV KT, Gao LJ, Hua X, Li F, et al
    The role of the globular heads of the C1q receptor in paclitaxel-induced human ovarian cancer cells apoptosis by a mitochondria-dependent pathway.
    Anticancer Drugs. 2017 Nov 23. doi: 10.1097/CAD.0000000000000567.
    PubMed     Text format     Abstract available


    September 2017
  3. ASSI T, Kourie HR, El Rassy E, Moussa T, et al
    Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole.
    Anticancer Drugs. 2017;28:931-933.
    PubMed     Text format     Abstract available


    August 2017
  4. REEVES PM, Abbaslou MA, Kools FRW, Poznansky MC, et al
    CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth.
    Anticancer Drugs. 2017 Aug 16. doi: 10.1097/CAD.0000000000000518.
    PubMed     Text format     Abstract available


    July 2017
  5. BORASKA JELAVIC T, Boban T, Brcic L, Vrdoljak E, et al
    Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel-carboplatin combination therapy in patients with epithelial ovarian cancer?
    Anticancer Drugs. 2017 Jul 3. doi: 10.1097/CAD.0000000000000538.
    PubMed     Text format     Abstract available


    May 2017
  6. PENDLEBURY A, DeBernardo R, Rose PG
    Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer.
    Anticancer Drugs. 2017 May 24. doi: 10.1097/CAD.0000000000000521.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: